摘要
目的：进行大鼠乳腺癌癌前病变结合肝郁证造模研究，观察大鼠在癌前病变病证结合造模阶段生物学行为、激素水平、血管生成等相关调控因子的改变，寻找癌前病变造模合理时间，健全乳腺癌癌癌前病变病证结合动物造模评价指标。方法：在中医理论的指导下，借鉴已有动物造模经验，采用二甲基苯蒽灌胃复制乳腺癌癌前病变大鼠模型，苯甲酸雌二醇和黄体酮肌注复制乳腺增生大鼠模型，夹尾激惹法复制肝郁证模型。实验大鼠随机分为空白对照组、二甲基苯蒽造模组、雌二醇造模组、二甲基苯蒽加夹尾造模组、雌二醇加夹尾造模组。实验开始后定期观察大鼠生物学行为的变化，在第8周、第12周分批活杀实验大鼠，观察各组大鼠乳房外形、5-羟色胺和乳腺组织形态改变，以及乳腺组织VEGF、Ki67、CD34、P63、C-erbB-2的免疫组化表达改变。结果：1、病证结合造模两组大鼠与单纯疾病造模两组大鼠比较，一般行为更符合肝郁证特点(P〈0．01)，5-羟色胺检测有显著差异(P〈0．01)；2、在组织形态方面，第8周二甲基苯蒽加夹尾造模组癌前病变出现率明显高于二甲基苯蒽造模组(P〈0．05)，第12周二甲基苯蒽加夹尾造模组与二甲基苯蒽造模组癌前病变和肿瘤出现率无显著差异(P〉0．05)，但均明显高于雌二醇造模组和雌二醇加夹尾造模组(P〈0．01)；3、免疫组化检测，二甲基苯蒽加夹尾造模组、二甲基苯蒽造模组VEGF、Ki67、C-erbB-2、CD34、P63表达与雌二醇造模组、雌二醇加夹尾造模组有显著差异(P〈0．01)，两组内免疫组化表达无显著差异(P〉0．05)。结论：二甲基苯蒽灌胃加夹尾激惹能成功复制大鼠乳腺癌癌前病变肝郁证模型。该模型大鼠的一般行为、神经内分泌表现符合中医肝郁证特点。这种病证结合造模方法能影响增殖细胞核抗原、血管内皮生长因子、原癌基因的表达，缩短癌前病变动物造模时间，提高造模成功率。同时，研究证实了CD34、P63表达对乳腺良恶性病变的鉴别作用，为评判乳腺癌癌前病变动物造模是否成功提供了可靠指标。
Objective:according to investigate the animal pattern of the depression syndrome ofthe liver breast precancerous,records breast precancerous change from the view ofangiogenesis,the hormone levels,in order to find a reasonable time to induction breastprecancerous in rats,and to provide a objective criterion for about breast precancerousmodel combining syndrome with disease in rats.Methods:combining the TraditionalChinese Medicine theory to experience of establish models,animal pattern of breastprecancerous was made by DMBA gavage,animal pattern of HMG was made by estroneand progesterone injection.stagnation syndrome of the liver modle was made by Jire law.Rats were randomly divided into 5 groups:the control group,the DMBA group,theestrone group,the DMBA folder tail group,the estrone folder tail group,these groupswere treated with different drugs.after 8 and 12 weeks,observing the shape of breast,microcirculation,5-HT,pathological changes of breast tissue,and the expression ofVEGF、Ki67、CD34、P63、C-erbB-2 by immunohistochemistry.Results:1、in the generalconduct,the comparative group more anastomosis the depression of the liver type to thetwo groups of the animal pattern(P〈0.01),there was significant difference (P〈0.05) inthe microcirculation and 5-HT;2、In the organization and morphology,after 8 weeks,theDMBA group's rate of breast precancerous higher than the DMBA folder tail group,after12 weeks,the DMBA group and the DMBA folder tail group is same (P〉0.05) in the rateof breast precancerous and canner occurrence,but higher than the estrone group and theestrone folder tail group(P〈0.01) 3、in Immunohistochemistry,the expression of VEGF、Ki67、C-erbB-2、CD34、P63 is difference in the DMBA groupand the DMBA folder tail group(P〈0.01),the two group is same repreat(P〉0.05).Conclusion:It is an successful method to induce animal pattern of thedepression of the liver type breast precancerous by gavage method and jire law.performance of general conduct、microcirculation、neuroendocrine are anastomosis withclinical features of stagnation of the liver type.the methods is to impact proliferating cellnuclear antigen,VEGF,expression of oncogene,shorten time about establish all models ofdisease,improve success rate.in addition,the study proved the expression of CD34 andP63 can differentiate Benign and malignant breast lesions,and provided reliable indicatorfor evaluating whether the animal pattern of breast precancerous is successful.
引文
[1]李永健，陈红风．乳腺癌癌前病变的中西医研究近况[J]．中医药通讯．2006，5(4)：63-66
[2]杨红鹰．乳腺癌癌前病变和早期乳腺癌[J]．中国临床医生．2003，31(2)：2-3
[3]阚秀．乳腺癌癌前病变[J]．中国实用外科杂志．2000，20(5)：261
[4]Ewing J.Precancerous diseases and precancerous lesions;especially in the breast [J].Med Record,1994,86:951-958
[5]俞孝廷．肿瘤病理学基础[M]．上海：上海科学技术出版社，1986：75
[6]Simpson JF,Page DL.The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer [J].Semin Oncol,1996,23(4):428-435
[7]傅西林．乳腺肿瘤[M]／／刘复生，刘彤华．肿瘤病理学．北京：北京医科大学中国协和医科大学联合出版社，1997：1599
[8]石松魁，刘俊田．乳腺癌癌前病变和早期乳腺癌的治疗进展[J]．中国实用外科杂志．2000，20(5)：303
[9]Lakhani SR.The transition from hyperplasia to invasive carcinoma of the breast[J].J Pathol,1999,187(3):272-278
[10]Page DL,Dupont WD.Anatomic markers of human premalignancy and risk of breast cancer[J].Cancer,1990,66(Suppl 6):1326-1335
[11]Carter CL,Corle DK,Micozzi MS,et al.A prospective study of the development of breast cancer in 16,692 women with benighbreast disease[J].Am J Epidimiol,1988,128(2):467-477
[12]Dupont WD,Page DL.Breast cancer risk associated with proliferative disease,age at first birth,and family hisory of breast cancer[J].Am J Epidemiol,1987,1225(3):769-779
[13]Page DL,DupontWD,Rogers LW,RadosMS.Atypical hyperplastic lesions of the female breast.A long-term follow-up stud [J].Cancer.1985,55(11):2698-2708
[14]Rockhill B,Spiegelman D,Byrne C,etal.Vaidation of the Gail etal Model of breast cancer risk prediction and implications for chemprevetion [J]Natl Cancer Inst,2001,93(5):366
[15]金宗浩．乳腺增生和乳腺癌[M]．上海：上海科学技术文献出版社，2003：11-14．
[16]阚秀．乳腺癌癌前病变和早期癌[J]．中国实用外科杂志，2000，20(5)：261-263．
[17]Ashikari R,Huvos AG,Snyder RE,et al.A clinicopathologic study of atypical lesions of the breast cancer,1974,33:310.
[18]王晓薇，丁建丽，王东凤，等．乳腺增生病与癌前病变[J]，山西医科大学学报，2000，36(2)：237-240．
[19]Allred DC,MedinaD.Introduction:models of premalignant breast disease [J].J MammaryGland BiolNeoplasia.2000,5(4):339-340.
[20]Henry J.Thompson,Meenakshi Singh.Ratmodels of premalignant breast disease [J].J MammaryGland BiolNeoplasia.2000,5(4):409-420.
[21]宋爱莉，叶林，李静蔚，等．乳复汤对乳腺非典型增生病证结合造模大鼠微循环的影响[J]．山东中医杂志，2003，22(10)：622-625．
[22]杨光伦，姚榛祥．外源性雌激素及三苯氧胺对大鼠乳腺癌癌前期病变的作用[J]．中华普通外科杂志，2001，16(2)：110-112．
[23]张毅，姜军，韩晓蓉，等．二甲基苯蒽诱导大鼠乳腺癌发生过程中周期蛋白D1、P53表达[J]．中华实验外科杂志，2002，19(1)：23-24
[24]Miller FR.Xenograftmodels of premalignant breast disease [J].J Mammary Gland Biol Neoplasia.2000,5(4):379-391.
[25]Dawson PJ,Wolman SR,TaitL,et a.1 A models for the evolution of cancer from proliferative breast disease [J]].AM J Path.1996,148:313-3191.
[26]Peng X,Wood S,Bratescu L,et a.1 Retinoids suppress premalignant MCF10AT but notmalignant MCF10CA1 a breast epithelial cells in vivo.Role of retinoic acid receptor beta2 expression [J].Cancer Lett.2005,222(2):153-163.
[27]Heppner GH,Wolman SR.MCF-10AT:A Model for Human Breast Cancer Development[J].Breast J.1999,5(2):122-129.
[28]何良新．乳腺增生病辨治四法[J]．中国中医药信息杂志，2000，7(3)：72．
[29]林毅，唐汉钧．现代中医乳房病学[M]．北京：人民卫生出版社，2003，第一版：101-108．
[30]宋爱莉，刘晓菲，李静蔚．乳腺癌癌前病变辨证与辨病规律研究述要[J]．中医药学刊，2005，(01)：45-47．
[31]李庆生，王志红，孙雯霞．再论病、症、证三者的概念及其关系[J]．湖南中医药导报，1996，8(4)：4-6
[32]申维玺，孙燕．论中医证的化学本质是蛋白质和肽及证本质的分子标准[J]．中国中西医结合杂志，1999，19(11)：696-698
[33]申维玺．分子生物学理论技术是架起中西医结合的桥梁[J]．新中医．2000，32(4)：3-4
[34]申维玺，孙燕．细胞因子网络紊乱是疾病的基本发病学原理[J]．医学研究通讯，2000，29(7)：1—4
[35]郭振球．21世纪微观辨证学发展的趋势[J]．中医药学刊，2001，18(1)：4—6
[36]柏正平．证候实质研究存在的问题及其对策[J]．湖南中医杂志，1994，10(2)：27
[37]危北海．循证医学与中医药学发展[J]．中国中西医结合消化杂志．2002，10(3)：131—134
[38]董敏．关于“证”客观化研究的现状、思路与方法[J]．湖北中医杂志，1996，18(4)：21-23
[39]陈涤平，陈四清，王瑜．南京中医药大学学报(自然科学版)2001，(3)：138—139
[40]华忠，陈民利．中医证动物模型的研究概况[J]．浙江中医杂志，1997，(8)：379—380
[41]王洪琦，许由玲主编．面向21世纪——中医基础理论研究的现状和未来[M]．北京：军事医学科学出版社，1999，第一版，55
[42]傅延龄．论“证”的性质、结构及证的研究[J]．中医天地，2003，(27)：5—10
[43]樊晰．略论郁证从肝治[J]．陕西中医，1989，10(3)：118—119
[44]赵益业．肝郁的免疫学探讨[J]．山东中医药大学学报，1997：21(1)：28—30
[45]顾永华，彭锦．中医肝郁证研究概况[J]．成都中医学院学报，1987，10(3)：56—58
[46]乔明琦．肝气逆、肝气郁两证客观指标的实验研究[J]．山东中医学院学报，1992，16(3)：23
[47]须惠仁．肝郁证的动物模型研究—激怒刺激对大鼠血流变学的影响[J]．中医杂志．1991，32(6)：364
[48]陈小野．实用中医证候动物模型学[M]．北京：中国协和医科大学、北京医科大学联合出版社．1993，第一版：264
[49]崔向阳，郝刚．肝气郁结证肝郁乘脾证病人甲皱微循环变化研究[J]．空军总医院学报，1990，6(2)：82．
[50]柴丽娜，杜惠兰．肝郁型月经病血液流变学及盆腔血流图的观察与分析[J]．山东中医杂志，1997，16(2)：61-62．
[51]王希浩，郝长源，罗伟．肝郁证月经病血液流变性的改变和意义[J]．中医研究，1997，10(1)：21-22．
[52]李松滨，杨丽珍，李宝龙．调肝汤对肝郁模型大鼠血液流变学的影响[J]．黑龙江中医药，2003，(3)：48-49．
[53]陈泽奇．肝气郁结证血浆去甲肾上腺素和肾上腺素测定结果分析[J]．中医药学报，1997，(5)：47．
[54]乔明琦，张惠云，陈雨振，等．肝郁证动物模型研究的理论思考[J]．中国医学学报，1997，12(5)：42
[55]鲁明，温建余，祝丽霞，等．肝郁证大鼠单胺类递质变化与性行为关系的实验研究[J]．中国男科学杂志，2002，16(3)：205
[56]毛海燕，叶林，叶向荣，等．肝郁证大鼠中枢神经递质变化的观察[J]．福建中医药．2002，33(2)：17
[57]文哲双，王志忠，朱毅．肝郁患者血清T、E2、PRL检测及其临床意义[J]．湖南中医学院学报，2000，2(2)：27
[58]王霞灵，周大桥．肝郁患者血清泌乳素测定临床意义探讨．[J]湖北中医杂志，1995，(5)：53
[59]严灿，张新春，邓中炎．肝主疏泄免疫学机制的临床与实验研究[J]．中国中医基础医学杂志，1995，1(3)：37．
[60]Welsch CW,House JL,HerrBL,et al.Enhancement of mammary carcinogenesis by high levels of dietary fat:a phenomenon dependent on adlibitum feeding[J].J Natl Cancer Inst,1990,82(20):1615.
[61]饶金才，李兰珍，陈云生，等．乳腺增生病动物模型的复制及病理类型[J]．中国病理生理杂志，1992，8(6)：671-672．
[62]孙敬方．动物实验方法学[M]．北京：人民卫生出版社，2005，第一版：21．
[63]陈家旭，杨维益．神经—内分泌—免疫网络研究概况及其与中医肝脏关系的探讨[J]．北京中医药大学学报，1995，18(4)：7-11
[64]刘胜春，吴凯南，历红元．血管生成在乳腺非典型增生病变过程中的作用[J]．中国肿瘤临床，1998，23(6)：421-424．
[65]陈建民．癌症患者血液高凝状态与活血化瘀治疗[J]．中西医结合杂志，1985，5(2)：89．
[66]高世嘉，庄逢源，安丽，等．乳腺增生病血液流变学特点和“乳腺2号”的药理作用[J]．中国血液流变学杂志，1993，3(3)：58．
[67]Carmeliet P,Jain RK Angiogenesis in cancer and other diseases [J]Nature 2000,407(6801):249-257.
[68]Zhang QX,Magovern CJ,Mack CA,et al.Vascular endothelial growth factor is the major angiogenic factor in omentum:mechanism of the omentum-mediated angiogenesis[J].Surg Res,1997,67(2):147-154.
[69]Neufeld G,Cohen T,Gengrinvitch S,et al.Vascular endothelial growth factor(VEGF) and its receptors[J].FASEB J,1999,13(1):9-22.
[70]Lichtenbeld He,Barendsz JAF,Van EN.Angigenic potential of malignant and non-malignant human breast tissues an in vivo angiogenesis model[J].Int Cancer,1998,77(4):445.
[71]Gruinelbretieve JM.Monique G,Gavoille A,et al.angiogenesis and risk of breast cancer in women with fibrocystic disease [J].Natl Cancer Inst,1994,86(8):635.
[72]Grurid AJ,Fisher L,Harris JR.Microvessel density and distribution in ductal carcinoma in situ of the breast [J].Natl Cancer Inst,1994,86(8):614.
[73]刘胜春，吴凯南，历红元．血管生成在乳腺非典型增生病变过程中的作用[J]．中国肿瘤临床，1998，23(6)：421-424．
[74]Gasparml G,Harris A.Clinical importance of the determination of tumor angiogenesis in breast carcinoma:much more than a new prognostic tool[J].Clin Oncol,1995,13(3):765-782.
[75]ZicheM,Gullino p.Angiogenesis and eoplastic progress ioninvitro,natl Cancer Inst,1982,69(2):483.
[76]Gruinelbretieve JM.Monique G,Gavoille A,et al.angiogenesis and risk of breast cancer in women with fibrocystic disease[J].Natl Cancer Inst,1994,86(8):635.
[77]Grurid AJ,Fisher L,Harris JR.Microvessel density and distribution in ductal carcinoma in situ of the breast[J].Natl Cancer Inst,1994,86(8):614
[78]Deering R,Bigler S,Brown M,etal.Microvascularity in benign prost atichyperplasia[J].Prostate,1995,26(3):111.
[79]Abulafia O,TriestW,ShereD,etal.Angiogenesis in endometrial hyperplasia and stage endometrial carcinoma.ObstetGynecol,1995,86(4):479.
[80]Dameron M,Volpert V,Tainsky A,etal.Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin[J].Science,1994,265:1582.
[81]Shibuya M,Tto M,Claesson W L.Structure and function of vascular endothelial growth factor receptor-1 and Curr Top.Microiol Immunol,1999,237:59.
[82]Williams GH,Romanowski P,Morris L,et al.Improved cervical smear assessment using antibodies against proteins that regulate DNA replication[J].Proc Natl Acad Sci USA,1998,95(25):14932-14937
[83]Bahnassy AA,Zekri AR,E1-Houssini S,et al.Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients[J].BMC Gastroenterol, 2004,12(4) 145-152
[84] Wohrley JD, Frid MG, Moiseeva EP, et al. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media[J]. J Clin Invest, 1999, 96(1):273-281
[85] Ganguli G, Abecassis J, Wasylyk B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basallayer of the epidermis [J]. EMBO J,2000,19 (19): 5135-5147
[86] Cao R, Brakenhielm E, Wahlestedt C. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF[J].Proc Natl Acad Sci USA, 2001,98(11): 6390-6395
[87] Isner JM, Asahara T.Angiogenesis and vasculogenesis a therapeutic strategies for postnatal neovascularization[J].Clin Invest, 1999,103(9): 1231-1236
[88] Moore T, Lee AHS. Expression of CD34 and Bcl-2 in phyllodestumours,fibroadenomas and spindle cell lesions of the breast [J]. Histopathology,2001, 38(1): 62-76.
[89] Silverman JS, Tamsen A. Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+fibroblasts and factor XIIIa+dendrophages [J].Histopathology, 1996,29(5):411-419.
[90] Lazard D, Sastre X, Frid MG, et al. Expression of smooth muscle- specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue [J].Proc Natl Acad Sci USA, 1993, 90(3): 999-1003.
[91] Shekhar MPV, Werdell J, Santner SJ, et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation:implications for tumour development and progression [J].Cancer Res,2001,61(4):1320-1326.
[92] Silberstein GB. Tumour?stromal interactions: role of the stroma in mammary development [J].Breast Cancer Res, 2001, 3(4):218-223.
[93] Kaufmann 0, Fietze E, Mengs J, et al Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentia-ted and undifferentiated carcinomas[J]. AmJ Clin Pathol,2001, 116: 823-830.
[94] Pellegrini G, Dellambra E, Golisano 0 et al. p63 identifies keratinocyte stem cells[J]. Proc Natl Acad Sci USA, 2001,98: 3156-3161.
[95] Barbareschi M, Pecciarini L. P63, a p5 homologue, is a selective nuclear marke of myoepithelial cells of the human breast[J]. Am J Surg Pathol,2001, 25:1054-1060.
[1]李永健，陈红风．乳腺癌癌前病变的中西医研究近况[J]．中医药通讯．2006，5(4)：63-66．
[2]杨红鹰．乳腺癌癌前病变和早期乳腺癌[J]．中国临床医生．2003，31(2)：2-3．
[3]阚秀．乳腺癌癌前病变[J]．中国实用外科杂志．2000，20(5)：261．
[4]Ewing J.Precancerous diseases and precancerous lesions,especially in the breast [J].Med Record,1994,86:951-958.
[5]俞孝廷．肿瘤病理学基础[M]．上海：上海科学技术出版社，1986：75．
[6]Simpson JF,Page DL.The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer [J].Semin Oncol,1996,23(4):428-435.
[7]傅西林．乳腺肿瘤[M]／／刘复生，刘彤华．肿瘤病理学．北京：北京医科大学中国协和医科大学联合出版社，1997：1599．
[8]石松魁，刘俊田．乳腺癌癌前病变和早期乳腺癌的治疗进展[J]．中国实用外科杂志．2000，20(5)：303．
[9]Lakhani SR.The transition from hyperplasia to invasive carcinoma of the breast[J].J Pathol,1999,187(3):272-278.
[10]Page DL,DupontWD,Rogers LW,RadosMS.Atypical hyperplastic lesions of the female breast.A long-term follow-up stud [J].Cancer.1985,55(11):2698-2708.
[11]Rockhill B,Spiegelman D,Byrne C,etal.Vaidation of the Gail etal Model of breast cancer risk prediction and implications for chemprevetion [J]J Natl Cancer Inst,2001,93(5):366.
[12]金宗浩．乳腺增生和乳腺癌．上海：上海科学技术文献出版社，2003：11-14．
[13]Ashikari R,Huvos AG,Snyder RE,et al.A clinicopathologic study of atypical lesions of the breast cancer,1974,33:310.
[14]王晓薇，丁建丽，王东风，等．乳腺增生病与癌前病变[J]．山西医科大学学报， 2000，36(2)：237-240．
[15]Allred DC,MedinaD.Introduction:models of premalignant breast disease [J].J MammaryGland BiolNeoplasia.2000,5(4):339-340.
[16]Henry J.Thompson,Meenakshi Singh.Ratmodels of premalignant breast disease [J].J MammaryGland BiolNeoplasia.2000,5(4):409-420.
[17]宋爱莉，叶林，李静蔚，等．乳复汤对乳腺非典型增生病证结合造模大鼠微循环的影响[J]．山东中医杂志，2003，22(10)：622-625．
[18]杨光伦，姚榛祥．外源性雌激素及三苯氧胺对大鼠乳腺癌癌前期病变的作用[J]．中华普通外科杂志，2001，16(2)：110-112．
[19]张毅，姜军，韩晓蓉，等．二甲基苯蒽诱导大鼠乳腺癌发生过程中周期蛋白D1、P53表达[J]．中华实验外科杂志，2002，19(1)：23-24．
[20]Miller FR.Xenograftmodels of premalignant breast disease [J].J Mammary Gland Biol Neoplasia.2000,5(4):379-391.
[21]Dawson PJ,Wolman SR,TaitL,et a.1 A models for the evolution of cancer from proliferative breast disease [J].AM J Path.1996,148:313-3191.
[22]Peng X,Wood S,Bratescu L,et a.1 Retinoids suppress premalignant MCF10AT but notmalignant MCF10CA1 a breast epithelial cells in vivo.Role of retinoic acid receptor beta2 expression [J].Cancer Lett.2005,222(2):153-163.
[23]Heppner GH,Wolman SR.MCF-10AT:A Model for Human Breast Cancer Development[J].Breast J.1999,5(2):122-129.
[24]宋爱莉，刘晓菲，李静蔚．乳腺癌癌前病变辨证与辨病规律研究述要．中医药学刊，2005，(01)：45—47．
[25]乔明琦．肝气逆、肝气郁两证客观指标的实验研究[J]．山东中医学院学报，1992，16(3)：23．
[26]须惠仁．肝郁证的动物模型研究—激怒刺激对大鼠血流变学的影响[J]．中医杂志．1991，32(6)：364．
[27]张小丽，闫惠勤，李重平．畅胃胶囊对肝郁证大鼠治疗作用的实验研究[J]．华西药学杂志．2002，17(3)：173—174．
[28]崔向阳，郝刚．肝气郁结证肝郁乘脾证病人甲皱微循环变化研究[J]．空军总医院学报，1990，6(2)：82．
[29]柴丽娜，杜惠兰．肝郁型月经病血液流变学及盆腔血流图的观察与分析[J]．山东中医杂志，1997，16(2)：61-62．
[30]乔明琦，张惠云，陈雨振，等．肝郁证动物模型研究的理论思考[J]．中国医学学报，1997，12(5)：42．
[31]鲁明，温建余，祝丽霞，等．肝郁证大鼠单胺类递质变化与性行为关系的实验研究[J]．中国男科学杂志，2002，16(3)：205．
[32]毛海燕，叶林，叶向荣，等．肝郁证大鼠中枢神经递质变化的观察[J]．福建中医药．2002，33(2)：17．
[33]文哲双，王志忠，朱毅．肝郁患者血清T、E2、PRL检测及其临床意义[J]．湖南中医学院学报，2000，2(2)：27．
[34]王霞灵．肝郁患者血清泌乳素测定临床意义探讨．[J]湖北中医杂志，1995，(5)：53．